Clinical trial · Interventional
The Effect of Cannabidiol on Lean Body Mass in Patients Receiving Chemotherapy
The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An intervention study on the effect of cannabidiol on lean body mass in cancer patients receiving chemotherapy, at the department of Clinical Oncology at Zealand University Hospital, Roskilde, Denmark. Fat free mass will be measured by bioimpedance spectroscopy. As secondary outcomes protein and energy intake, nausea, taste alterations and life quality will be assessed by oral interviews and questionnaires.
Conditions
Conditions (7)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Appetitive Behavior | — | UNRESOLVED | — |
| Cachexia | — | UNRESOLVED | — |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Cannabis | — | UNRESOLVED | — |
| Emesis | — | UNRESOLVED | — |
| Lean Body Mass | — | UNRESOLVED | — |
| Nausea | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cannabidiol | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention group
- description
- Cancer patients receiving cannabidiol
- interventionNames
- Drug: Cannabidiol
- type
- NO_INTERVENTION
- label
- Control group
- description
- Cancer patients not receiving cannabidiol
Primary outcomes (1)
- measure
- Number of patients with change in lean body mass from baseline.
- timeFrame
- 10 weeks
- description
- Changes in lean body mass measured at baseline and before each chemotherapy treatment (scheduled for every three weeks) measured in kg by bioimpedance. Changes are assessed as change in percentage of total lean body mass weight.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * A diagnosis of cancer * Fulfill criteria for starting chemotherapy * Must be able to stand upright * Have the possibility of contact by telephone * No previous treatment with taxanes or platinums * Scheduled to undergo lest 4 courses of paclitaxel or 4 courses of oxaliplatin based chemotherapy * If female and fertile, must have been menopausal for 1 year or negative pregnancy test at inclusion and use approved contraceptive measures Exclusion Criteria: * Pregnant * Breastfeeding * Unable to complete patient reported outcomes (PRO)-measurements * Previously received taxanes or platinum-based chemotherapy * Use of cannabinoids. If in use, treatment must be stopped 4 days prior to inclusion * If using any anti epileptic or antidepressant medicine. Treatment must be stable (no changes in dosing in last 30 days) prior to inclusion. However, any treatment with Clobazam is not allowed due to major interaction with cannabidiol.
References
Publications (0)
Data not yet available